Indian Panel Flaws Biosimilar Humira Package Insert
This article was originally published in Scrip
Executive Summary
An Indian expert panel has flagged a clutch of deficiencies in the package insert of Reliance Life Sciences' biosimilar version of AbbVie's blockbuster biologic, Humira (adalimumab), including some inconsistencies around data and dosing.
You may also be interested in...
Novartis Faces Another Challenge To Entresto In India
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
India-China Tango: Can Gland Sustain Listing Luster?
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A Peek At How Janssen’s Supply Chain Withstood COVID-19 Disruptions
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.
Need a specific report? 1000+ reports available
Buy Reports